Maura L. Gillison

The University of Texas MD Anderson Cancer Center

Full Professor(heuristic)

Head and Neck Cancer Studies · Otorhinolaryngology

h-index98

i10-index224

Publications630

Citations60,123

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 158

Abstract LB485: Integrative analyses of cervical cancer and patient-derived organoids uncover signaling and metabolic circuits associated with therapy-resistant
Cancer Research · 2026-04-17
Abstract 49: The PER3-RORB axis defines a tumor-suppressive circadian state associated with improved survival in head and neck squamous cell carcinoma.
Cancer Research · 2026-04-03
Supplementary Table 11 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31
Supplementary Table 4 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31
Figure 1 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31
Supplementary Figure 1 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31
Supplementary Table 2 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31
Supplementary Table 13 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31
Table 2 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31
Supplementary Figure 6 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31
Supplementary Figure 5 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31
Supplementary Table 3 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31
Table 1 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31
Supplementary Table 10 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31
Supplementary Figure 4 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31
Table 3 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31
Supplementary Table 8 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31
Figure 2 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31
Figure 3 from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31
Data from The KRAS-Variant and Cetuximab in HPV-Positive Oropharyngeal Cancer: Results from the NRG/RTOG 1016 Trial
2026-03-31

Open author page on OpenAlex →